Theravance Biopharma, Inc.
Price Action
Technical Summary
EMERGING TRENDTheravance Biopharma, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 54), indicating performance broadly in line with the market. Earnings growth of 127% provides fundamental context to the price action. Investors should exercise caution due to high volatility (53% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $16.68 | +1.53% | ABOVE |
| 50 SMA | $15.81 | +7.18% | ABOVE |
| 100 SMA | $17.51 | -3.27% | BELOW |
| 150 SMA | $17.04 | -0.57% | BELOW |
| 200 SMA | $16.03 | +5.69% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TBPH in an uptrend right now?
TBPH has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is TBPH overbought or oversold?
TBPH's RSI (14) is 55. The stock is in neutral territory, neither overbought nor oversold.
Is TBPH outperforming the market?
TBPH has a Relative Strength (RS) Rating of 54 out of 99. TBPH is performing about average compared to the market.
Where is TBPH in its 52-week range?
TBPH is trading at $16.94, which is 81% of its 52-week high ($21.03) and 68% above its 52-week low ($8.33).
How volatile is TBPH?
TBPH has a Beta of 0.89 and 52-week volatility of 53%. It's less volatile than the S&P 500 - generally more stable.